Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling

Journal of Neural Transmission, Supplement

Volumn 60, Issue , 2000, Pages 77-100

  Tatton, W G ^a   Chalmers Redman, R M E ^a   Elstner, M ^a   Leesch, W ^a   Jagodzinski, F B ^a   Stupak, D P ^a   Sugrue, M M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; APOPTOSIS INHIBITOR; DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NUCLEAR RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SELEGILINE; UNCLASSIFIED DRUG;

APOPTOSIS; CONFERENCE PAPER; DNA REPLICATION; ENERGY METABOLISM; ENZYME KINETICS; EXOCYTOSIS; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; HUMAN CELL; NERVE DEGENERATION; NEUROPROTECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BRAIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; SELEGILINE; SIGNAL TRANSDUCTION;

EID: 0034520652     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-3-7091-6301-6_5     Document Type: Article

References (206)

1. DNA strand breaks in Alzheimer's disease
2. Microanatomical changes in the frontal cortex of aged rats: Effect of L-deprenyl treatment
3. Influence of treatment with L-deprenyl on the structure of the cerebellar cortex of aged rats
4. Neuroanatomy of aging brain. Influence of treatment with L-deprenyl
5. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay
6. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
7. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition
8. Reciprocal changes in the expression of Bcl-2 and Bax in hypoglossal nucleus after axotomy in adult rats: Possible involvement in the induction of neuronal cell death
9. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease [In Process Citation]
10. An intriguing new lead on Huntington's disease
11. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells
12. Structure/function in neuroprotection and apoptosis
13. An arenavirus RING (zinc-binding) protein binds the oncoprotein PML and relocates PML nuclear bodies to the cytoplasm
14. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING
15. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
16. Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2
17. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH
18. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man
19. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum
20. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush
21. Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase
22. Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer
23. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism
24. Mechanisms of nerve cell death: Apoptosis or necrosis after cerebral ischaemia
25. Glucose protection from MPP+-induced apoptosis depends on mitochondrial membrane potential and ATP synthase
26. The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro
27. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: Evidence that GAPDH is upregulated by p53
28. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
29. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia
30. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
31. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
32. Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts
33. Oxygen deprivation but not a combination of oxygen, glucose, and serum deprivation induces DNA degradation in mouse cortical neurons in vitro: Attenuation by transgenic overexpression of CuZn-superoxide dismutase
34. Possible role of apoptosis in Alzheimer's disease
35. Time course of axotomy-induced apoptotic cell death in facial motoneurons of neonatal wild type and bcl-2 transgenic mice
36. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease
37. P53- and CD95-associated apoptosis in neurodegenerative diseases
38. Role of oxidative stress in the manganese and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced apoptosis in PC12 cells
39. Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes
40. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons
41. Immediate-early gene protein expression in neurons undergoing delayed death, but not necrosis, following hypoxic-ischaemic injury to the young rat brain
42. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
43. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and Na+: Implications for neurodegeneration
44. Controversies in the therapy of Parkinson's disease
45. Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells
46. Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone
47. Cumulative effects of irreversible MAO inhibitors in vivo
48. Oxidative stress: Role of mitochondria and protection by glutathione
49. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B
50. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
51. Effects of NAD(+) binding on the luminescence of tryptophans 84 and 310 of glyceraldehyde-3-phosphate dehydrogenase from Bacillus stearothermophilus
52. Immunolabelling of the cytoplasm and processes of apoptotic facial motoneurons following axotomy in the neonatal rat
53. Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration
54. The histological effects of intracerebral injection or infusion of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and MPP+ (1-methyl-4-phenylpyridinium) in rat and mouse
55. Terminal deoxyribonucleotidyl transferase (EC 2.7.7.31)
56. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
57. DNA fragmentation indicative of apoptosis following unilateral cerebral hypoxia-ischemia in the neonatal rat
58. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
59. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons
60. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture
61. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture
62. Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis
63. Nitric oxide-induced modification of glyceraldehyde-3-phosphate dehydrogenase with NAD(+) is not ADP-ribosylation
64. Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat
65. Understanding cell death in Parkinson's disease
66. (-)-Deprenyl alters the time course of death of axotomized facial motoneurons and the hypertrophy of neighboring astrocytes in immature rats
67. Effect of selegiline on dopamine concentration in the striatum of a primate
68. Chromatin condensation during apoptosis requires ATP
69. Shrinkage necrosis: A distinct form of cell death
70. DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect?
71. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders
72. Changes of p53 in the brains of patients with Alzheimer's disease
73. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease
74. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity
75. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia
76. Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem
77. On the question of apoptosis in the parkinsonian substantia nigra
78. Selegiline enhances survival and neurite outgrowth of MPP(+)-treated dopaminergic neurons
79. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium
80. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
81. Mitochondrial control of apoptosis
82. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus
83. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out
84. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
85. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey
86. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian-Danish 5-year study
87. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ
88. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition
89. Detection of actin cleavage in Alzheimer's disease
90. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease
91. Deprenyl in Parkinson's disease
92. Clinical trials of neuroprotection in Parkinson's disease: Long-term selegiline and alpha-tocopherol treatment
93. Characterization of spinal motoneuron degeneration following different types of peripheral nerve injury in neonatal and adult mice
94. Apoptosis inducing factor (AIF): A phylogenetically old, caspase-independent effector of cell death
95. Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome
96. DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology
97. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus
98. Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease
99. Cerebral ischemia produces laddered DNA fragments distinct from cardiac ischemia and archetypal apoptosis
100. The neuroprotective and neuronal rescue effects of (-)-deprenyl
101. Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease
102. Oxygen free radicals enhance the nitric oxide-induced covalent NAD(+)-linkage to neuronal glyceraldehyde-3-phosphate dehydrogenase
103. Upregulation of the antiapoptotic protein Bcl-2 may be an early event in neurodegeneration: Studies on Parkinson's and incidental Lewy body disease
104. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells
105. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
106. The permeability transition pore complex: A target for apoptosis regulation by caspases and Bcl-2-related proteins
107. Apoptosis in neural development and disease
108. Reconstructing a disease: RARa, its fusion protein oartners and their roles in the pathogenesis of acute promyelocytic leukemia
109. Modification of macrophage glyceraldehyde-3-phosphate dehydrogenase in response to nitric oxide
110. Effect of macromolecular crowding upon the structure and function of an enzyme: Glyceraldehyde-3-phosphate dehydrogenase
111. Dopaminergic neurotoxins mptp and mpp-+ inhibit activity of mitochondrial nadh-ubiquinone oxidoreductase
112. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion
113. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease
114. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease
115. Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat
116. Histochemical detection of apoptosis in Parkinson's disease
117. Bcl-2 Protein is increased in the brain from parkinsonian patients
118. The soluble form of Fas molecule is elevated in parkinsonian brain tissues
119. Selegiline in de novo parkinsonian patients: The Finnish study
120. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion
121. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro
122. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion
123. Apoptosis-related protein expression in the hippocampus in Alzheimer's disease
124. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold)
125. The cell division cycle and the pathophysiology of Alzheimer's disease
126. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
127. Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells
128. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: Increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants
129. Overexpression of HA-Bax but not Bcl-2 or Bcl-XL attenuates 6-hydroxydopamine-induced neuronal apoptosis
130. The effect of deprenyl and levodopa on the progression of Parkinson's disease
131. Mechanism of MPP(+)-induced cytotoxicity in human neuroblastoma SH-SY5Y
132. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain
133. (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells
134. R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium
135. Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress
136. L-deprenyl protects injured retinal precursor cells in vitro
137. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+
138. (-)-Deprenyl attenuates spinal motor neuron degeneration and associated locomotor deficits in rats subjected to spinal cord ischemia
139. Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl
140. Glycolytic enzymes as DNA binding proteins
141. Axotomy-induced apoptotic cell death of neonatal rat facial motoneurons: Time course analysis and relation to NADPH-diaphorase activity
142. Deprenyl reduces the death of motoneurons caused by axotomy
143. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
144. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo
145. Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis
146. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis
147. Glyceraldehyde-3-phosphate dehydrogenase: Nuclear translocation participates in neuronal and nonneuronal cell death
148. Mitochondrial complex I deficiency in Parkinson's disease
149. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
150. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures
151. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
152. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage
153. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP
154. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis
155. Nuclear translocation of GAPDH-GFP fusion protein during apoptosis
156. MPP+ induced apoptotic cell death in SH-SY5Y neuroblastoma cells: An electron microscope study
157. DATATOP: A decade of neuroprotective inquiry. Deprenyl and tocopherol antioxidative therapy of parkinsonism
158. Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase
159. New insights into an old protein: The functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase
160. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
161. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis
162. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death
163. Immunohistochemical evidence for apoptosis in Alzheimer's disease
164. Bax protein expression is increased in Alzheimer's brain: Correlations with DNA damage, Bcl-2 expression, and brain pathology
165. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
166. Reduced mitochondrial membrane potential and altered responsiveness of a mitochondrial membrane megachannel in p53-induced senescence
167. Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain
168. Mitochondria as regulators of apoptosis: Doubt no more
169. Mitochondrial release of caspase-2 and -9 during the apoptotic process
170. Molecular characterization of mitochondrial apoptosis-inducing factor
171. Origin and functional consequences of the complex I defect in Parkinson's disease
172. Biochemical abnormalities and excitotoxicity in Huntington's disease brain
173. Vitamin E prevents apoptosis in cortical neurons during hypoxia and oxygen reperfusion
174. Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with cloned GAPDH cDNAs
175. MPTP neurotoxicity to cerebellar Purkinje cells in mice
176. Roles of Bcl-2 and caspases in hypoxia-induced neuronal cell death: A possible neuroprotective mechanism of peptide growth factors
177. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH accumulation and neuronal apoptosis in Parkinson's disease
178. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
179. Confocal microscopy as a tool to examine DNA fragmentation, chromatin condensation and other apoptotic changes in Parkinson's disease
180. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
181. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration
182. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
183. Apoptosis in neurodegenerative diseases: The role of mitochondria
184. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
185. Apoptosis in neurodegenerative disorders: Potential for therapy by modifying gene transcription
186. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
187. Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency
188. Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum
189. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl
190. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis
191. Annexin V labels apoptotic neurons following hypoxia-ischemia
192. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study
193. Distinct monoamine oxidase a and b populations in primate brain
194. Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem
195. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord
196. Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity
197. Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition
198. Cell death and apoptosis regulating proteins in Parkinson's disease - A cautionary note
199. 1-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons
200. Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
201. Induction of the mitochondrial permeability transition causes release of the apoptogenic factor cytochrome c
202. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2
203. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus
204. Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus
205. Nitric oxide in the nervous system
206. Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl